Takeda Inks $2.2 Billion License Deal for AC Immune’s Alzheimer’s Immunotherapy
Takeda has secured an exclusive global option and license agreement for AC Immune’s promising active immunotherapy targeting amyloid beta for
Read moreTakeda has secured an exclusive global option and license agreement for AC Immune’s promising active immunotherapy targeting amyloid beta for
Read moreThe Hamburg headquartered publicly listed drug discovery and development company Evotec and Variant Bio, a US-based biotech company leveraging the
Read moreFrench biotech Medincell announced on Tuesday entering into a collaboration with AbbVie, to co-develop up to six innovative long-acting injectable
Read moreVertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc., a biotechnology firm dedicated to pioneering protein-based immunotherapies, jointly announced the signing
Read moreBristol Myers Squibb has added a premier radiopharmaceutical platform to its portfolio with the acquisition of RayzeBio, a radiopharmaceutical therapeutics
Read moreAmerican multinational pharmaceutical company Bristol Myers Squibb and Karuna Therapeutics, Inc. (“Karuna”) have announced that they have entered into a
Read moreAstraZeneca announced it has agreed to acquire Gracell Biotechnologies Inc, which is set to advance its cell therapy portfolio across
Read moreAbbVie is set to acquire ImmunoGen in a $10.1B deal which encompasses ImmunoGen’s first-in-class antibody-drug conjugate (ADC) cancer treatment ELAHERE®
Read moreBoehringer Ingelheim has confirmed the acquisition of T3 Pharmaceuticals AG, a Swiss clinical-stage biotech company thereby expanding its immuno-oncology portfolio.
Read moreStressMarq Biosciences, a pioneer in the development and commercialization of unique fibrilized and oligomeric protein preparations to propel the study
Read more